Apr 11 2019

Elaine’s group discovered a cardiac glycoside restrains EGFR-related and EGFR-independent NSCLC cell proliferation with distinct treatment mechanism

Non-small cell lung cancer (NSCLC) is the predominant histological type of lung cancer and is characterized by the highest mortality and incidence rates among these types of malignancies (1, 2). Traditional Chinese medicine (TCM) has been applied for centuries in China (3, 4). Cardiac glycosides, a class of natural products, have been identified as a […]

Read More

By • News, Research • 0

Jul 1 2020

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

Gang Chen, Alexander C. Huang, et al. Published at Nature on 08 August 2018 Tumor cells evade immune surveillance by upregulating the surface expression of programmed death-ligand 1 (PD-L1), which interacts with programmed death-1 (PD-1) receptor on T cells to elicit the immune checkpoint response. Anti-PD-1 antibodies have shown remarkable promise in treating tumors, including lung cancer and […]

Read More

By • Oncology News • 0

Jun 25 2019

MSCO annual meeting held on 2019-5-18

MSCO and Kiang Wu Hospital Oncology Image Seminar was held on 2019-5-18 at Macau. Attendance came form China mainland, HK, Taiwan and Macau. There were 4 sections in the seminar, focus on prostate cancer, breast cancer, lung cancer and lymphoma. In each section, speakers talks about recent progress in disease specific image characteristics, advance in […]

Read More

By • MSCO Activities • 0

Jun 25 2019

Notebook: Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Nature 2019 May; 569(7756) Immunotherapy combined with PD-1 and CTLA-4 is effective for renal melanoma and non-small cell lung cancer.However, thiscomes at the cost of frequent, serious immune-related adverseevents, necessitating a reduction in the recommended dose ofipilimumab that is given to patients. Immune-related adverse events that result from therapy with checkpoint inhibitors are usually satisfactorily treated […]

Read More

By • Oncology News • 0

Jun 25 2019

Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy

Lee Schwartzberg,Beata Korytowsky,John R. Penrod,Ying Zhang, T. Kim Le,Cory Batenchuk, Lee Kru Lung cancer is the first most common malignancy in the wild word, and the leading cause of cancer-related mortality. Approximately 85% of lung cancers are non-small-cell lung cancer (NSCLC). More than half of all lung cancers in the United States are diagnosed at […]

Read More

By • Oncology News • 0

Apr 11 2019

MSCO seminar on MTD for GI cancers

On December 8, 2019. MSCO held a MTD meeting with team for 6th Affiliated hospital of Sun Yet-sen university (Guangzhou), 5th Affiliated hospital of Sun Yet-sen university (Zhuhai) and Cancer centre of Sun Yet-sen university (Guangzhou). Several cases were discussed in the meeting, regard the treatment sequence of chemo and operation procedure. Use of IO […]

Read More

By • MSCO Activities • 0

Apr 11 2019

MSCO conference on Immuno Oncology

On March 23, MSCO held a conference on Immuno- Oncology in MGM. Experts from China and Macau were joined and shared their opinions on this hot topic. Two IO drugs has been licensed in China and patients can get assess to IO treatment more easily than before. However many issues were now became more and […]

Read More

By • MSCO Activities • 0

Mar 8 2019

Notebook: Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment

Dr. Best S A et al recently report their finding on NSCLC and KEAP1/NRF2 and PI3K Pathways[1].   It is well known that non-small cell lung cancer is the most common type of lung cancer, with a lower survival rate in most cancer.Adenocarcinoma (ADC) is the major histological subtype of lung cancer and the KEAP1/NRF2 pathway […]

Read More

By • News • 0

Mar 8 2019

Notebook: SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

Recently Dr. Mainardi S, et al. found SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer. Research published at Nature Medicine on May 28, 2018. Lung cancer is the most common cause of cancer death worldwide, about 1.6 million deaths every year. Non-small cell lung cancer (NSCLC) is the primary type of lung cancer […]

Read More

By • News • 0

Mar 8 2019

Notebook：A defined commensal consortium elicits CD8 T cells and anti-cancer immunity

Recently, Dr. Takeshi Tanoue et al report relationship between CD8 T-cells and anti-cancer immunity. This paper was published on Nature volume 565, pages600–605 (2019) Dysbiosis of commensal microbiota can contribute to cancer onset, progression and therapy response through effects on anti-tumor immunity1-4.The currently studies have now advanced our understanding of local microbiota immunomodulation and gaveustheinsight into the potential of […]

Read More

By • News • 0

1 2 3 4 5 >»

↑

Copyright@MSCO. Macau Society of Clinical Oncology, 2017.